Adalimumab in ulcerative colitis: Ready for prime time

被引:10
|
作者
Danese, Silvio [1 ]
机构
[1] Humanitas Clin & Res Ctr, I-20089 Milan, Italy
关键词
Anti-TNF alpha; Inflammatory bowel disease; INFLAMMATORY-BOWEL-DISEASE; MAINTENANCE THERAPY; CROHNS-DISEASE; LOST RESPONSE; OPEN-LABEL; INFLIXIMAB; INTOLERANCE; INDUCTION; EFFICACY; MANAGEMENT;
D O I
10.1016/j.dld.2012.05.021
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Ulcerative colitis is one of the two main types of inflammatory bowel disease and is a chronic condition with a significant impact on health-related quality of life. For many patients, currently available treatment options do not provide adequate efficacy or are poorly tolerated. Efforts to identify new agents for the treatment of ulcerative colitis have focused mainly on targeting tumour necrosis factor alpha, a proinflammatory cytokine believed to play a pivotal role in the initiation and progression of the disease. Until recently, there was only one anti-tumour necrosis factor alpha agent approved for treatment of ulcerative colitis, infliximab, although there were several other such agents approved for the related condition, Crohn's disease, including adalimumab. This year (2012), adalimumab has been approved by the European Medicines Agency for the treatment of ulcerative colitis. Here, the current evidence regarding use of adalimumab in the treatment of ulcerative colitis is reviewed, with results indicating that adalimumab has compelling efficacy in the treatment of moderate-to-severe ulcerative colitis. (C) 2012 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:8 / 13
页数:6
相关论文
共 50 条
  • [1] Is histologic remission in ulcerative colitis ready for prime time?
    Guardiola, Jordi
    Arajol, Claudia
    Armuzzi, Alessandro
    DIGESTIVE AND LIVER DISEASE, 2017, 49 (12) : 1334 - 1335
  • [2] Early Intervention in Ulcerative Colitis: Ready for Prime Time?
    Solitano, Virginia
    D'Amico, Ferdinando
    Zacharopoulou, Eirini
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (08) : 1 - 12
  • [3] Cyclosporine Enema in Conventional ± Immunomodulator Refractory Distal Ulcerative Colitis: Ready for Prime Time or Hype?
    Mahesh, Venkataswamy N.
    Campbell, Rachel
    Ahluwalia, Navneet K.
    GASTROENTEROLOGY, 2010, 138 (05) : S700 - S700
  • [4] CYCLOSPORINE ENEMA IN CONVENTIONAL ± IMMUNOMODULATOR REFRACTORY DISTAL ULCERATIVE COLITIS: READY FOR PRIME TIME OR HYPE
    Mahesh, V. N.
    Campbell, R.
    Ahluwalia, N. K.
    GUT, 2009, 58 : A44 - A44
  • [5] Adalimumab in patients with ulcerative colitis
    Balatsos, V.
    Anastasiou, Th.
    Karoumpalis, I.
    Katselis, I.
    Vagia, A.
    Skandalis, N.
    ANNALS OF GASTROENTEROLOGY, 2010, 23 (01): : 64 - 66
  • [6] The economics of adalimumab for ulcerative colitis
    Xie, Feng
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (03) : 373 - 377
  • [7] CURCUMIN USE IN ULCERATIVE COLITIS - IS IT READY FOR PRIME TIME? A SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL TRIALS
    Chandan, Saurabh
    Mohan, Babu P.
    Chandan, Ojasvini Choudhry
    Ahmad, Rizwan
    Tummala, Hemachand
    Singh, Shailender
    Dhawan, Punita
    Singh, Amar B.
    GASTROENTEROLOGY, 2019, 156 (06) : S644 - S644
  • [8] Curcumin use in ulcerative colitis: is it ready for prime time? A systematic review and meta-analysis of clinical trials
    Chandan, Saurabh
    Mohan, Babu P.
    Chandan, Ojasvini C.
    Ahmad, Rizwan
    Challa, Abhishek
    Tummala, Hemachand
    Singh, Shailender
    Dhawan, Punita
    Ponnada, Suresh
    Singh, Amar B.
    Adler, Douglas G.
    ANNALS OF GASTROENTEROLOGY, 2020, 33 (01): : 53 - +
  • [9] Vedolizumab vs adalimumab for ulcerative colitis
    Feetham, Laura
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (05): : 337 - 337
  • [10] Adalimumab in ulcerative colitis: hypes and hopes
    Fiorino, Gionata
    Peyrin-Biroulet, Laurent
    Repici, Alessandro
    Malesci, Alberto
    Danese, Silvio
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (01) : 109 - 116